Skip to main content

Table 2 FNDC3B expression associated with clinicopathological characteristics (logistic regression)

From: Identification of fibronectin type III domain containing 3B as a potential prognostic and therapeutic target for pancreatic cancer: a preliminary analysis

Characteristics

Total (N)

Odds ratio (OR)

P value

T stage (T3 & T4 vs. T1 & T2)

176

1.793 (0.811–3.962)

0.149

N stage (N1 vs. N0)

173

2.763 (1.379–5.536)

0.004

M stage (M1 vs. M0)

84

1.898 (0.189–19.072)

0.586

Pathologic stage (Stage II & Stage III & Stage IV vs. Stage I)

175

2.847 (1.049–7.726)

0.040

Radiation therapy (Yes vs. No)

163

0.846 (0.425–1.683)

0.633

Primary therapy outcome (PR & CR vs. PD & SD)

140

0.565 (0.286–1.116)

0.100

Age (> 65 vs. ≤ 65)

178

0.439 (0.241–0.801)

0.007

Race (White vs. Asian & Black or African American)

174

1.083 (0.397–2.951)

0.876

Gender (Male vs. Female)

178

1.199 (0.664–2.172)

0.547

Residual tumor (R1 & R2 vs. R0)

164

2.054 (1.068–3.952)

0.031

Histologic grade (G3 & G4 vs. G1 & G2)

176

1.913 (0.979–3.738)

0.058

Anatomic neoplasm subdivision (Other vs. Head of Pancreas)

178

0.719 (0.352–1.470)

0.366

Alcohol history (Yes vs. No)

166

0.708 (0.378–1.326)

0.281

Smoker (Yes vs. No)

145

1.660 (0.856–3.219)

0.134

History of chronic pancreatitis (Yes vs. No)

142

0.898 (0.286–2.818)

0.854

History of diabetes (Yes vs. No)

147

0.855 (0.407–1.796)

0.680

  1. Total patients’ number is inconsistent in all variates due to lack of patient’s information for some cases
  2. CR complete response, FNDC3B fibronectin type III domain containing 3B, G1: well-differentiated, G2: moderately-differentiated, G3: poorly-differentiated, G4: undifferentiated, M: metastasis, N: lymph node, PC pancreatic cancer, PR partial response, PD progressive disease, SD stable disease, T: tumor
  3. Bold values indicate that P < 0.05 which are statistically significant